Further, insulin is adipogenic and thus contributes to obesity whereas metformin is associated with weight loss, making it difficult to interpret whether GLP-1 receptor agonist or the comparator medication is truly altering malignancy risk. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.